Thursday, 15 June 2017 325 normal (1.2x10 3 /μl; normal range 1.1 to 3.2x10 3 /μ l) but peripheral B cell numbers were markedly diminished (37/μl, normal range: 100 -500/μl). While the percentage of naïve B cells (53%) and marginal zone like B cells (10.5%) were within normal range, the percentage of class-switched memory B cells was high (28.2%). To assess the in vitro class switch capacity to IgE the number of IgE class-switched cells after 9 days of culture was determined by counting the events in the IgG/A/D-IgE+ gate. 2 was used for monitoring activity of RV Results: 63 patients of RV were identified, with a study period prevalence of 0.7%, in our RA cohort. 33 (52.4%) patients were female. Mean age of patients was 50.7±11.5 years with median duration of RA being 6 years. Involvement of Peripheral Nervous System (PNS) was the commonest manifestation of RV in 52/63 (82.5%) patients followed by skin in 34/63 (53.9%) patients. Rheumatoid Nodule was seen in 14/ 63 (22.2%) patients. Percentage of current and ex-smokers combined,was same as rheumatoid nodule prevalence. 52 (82.5%) patients had biopsy evidence of vasculitis.26/51 (50.9%)patients were started on mycophenolate mofetil, 13/51 (25.5%)patients on cyclophosphamide, 8/51 (15.7%) patients on azathioprine, 4/51 (7.8%) patients on Methotrexate as immunosuppressive (IS) agent along with mean dose of 46.6±13.7 (0.86±0.23mg/kg/day) prednisolone. Additionally, Rituximab & IVIg were used in 2 patients each respectively. 3 months after initiation of immunosuppression 26/50 (52%) patients on follow-up were in remission and 39/47 (82.9%) patients attained remission at 6 months. Mean time to achieve remission was 151.1±86.3 days. All IS agents were equally effective in inducing remission at 3 and 6 months and showed statistically similar BVAS reduction at 3 and 6 months from baseline (t test & chi-square test). 7 (11.2%) deaths noted in the cohort at their respective last visit during 195.3 patient years cumulative follow up. Multiple regression analysis showed that at baseline, presence of PNS involvement, eosinophilia, thrombocytosis, higher BVAS score and higher steroid requirement were predictors of persistently active vasculitis and absence of eye involvement and higher hemoglobin % at baseline were predictors for remission, at 3 months (p<0.05). 4/50 (8%) patients had relapse of vasculitic symptoms. 2 and 5 year survival rates were 96.2% and 83.9% respectively Conclusions: Our cohort of Asian Indian RV was comparitively younger with lesser RA duration, less percentage of ever-smokers, lesser rheumatoid nodule prevalence, higher PNS involvement with better survival/mortality rates compared to published literature. All IS agents showed equal rates of BVAS remission & BVAS reduction at 3 and 6 months of treatment References: 
THU0323 THE INCIDENCE RATES OF ANCA-ASSOCIATED VASCULITIDES IN NORTHERN GERMANY (SCHLESWIG-HOLSTEIN) REMAIN STABLE BETWEEN
Objectives: To assess the incidence of ANCA-associated vasculitides (AAV) in a stable population by registering all newly diagnosed patients in a large region in Northern Germany. To investigate the epidemiology and pattern of AAV over seventeen years in a prospective study. Methods: Between 1/1/98 and 31/12/14 all newly diagnosed cases of AAV (Granulomatosis with polyangiitis (GPA), microscopic polyangitis (MPA), eosinophilic granulomatosis with polyangitis (EGPA)) as defined by the Chapel Hill Consensus Conference 1992 were identified in a large mixed rural/urban northern German region consisting of 2,83 million habitants in a population-based prospective study. The following sources were explored on a regular basis: (a) departments of all hospitals, including their outpatient clinics; (b) all departments of pathology, and (c) the reference immunological laboratories serving the catchment area. All cases were re-evaluated by the authors. Results: Within the observation period of seventeen years 551 patients were identified as having a new diagnosis of AAV in the catchment area, the incidence rate was 12 (range 8 -16)/million/year. GPA represents 70% of the AAV with an incidence rate of 7.9 (range 6-12)/million/year (95% CI 1;11 -5;19), MPA with an incidence rate of 2.4 (range 1-5)/million/year (CI 0;3 -1;9) and EGPA 1.1 (range 0-2)/million/year (CI 0;4). Incidence rates of GPA were on average three times higher than those of MPA and seven times higher than CSS. The incidence rates were stable between 1998 and 2014, our observations did not reveal significant differences. Gender differences were not observed. People diagnosed with MPA were on average 66.4 years old. Conclusions: Results of our unique population based vasculitis register over seventeen years assessing the incidence of AAV in a region of 2.83 million habitants in northern Germany demonstrate stable incidence rates for AAV. Variances between years have been observed, but no pattern or periodicity.
Compared to other studies investigating small regions or referral centers the incidence rates for AAV were comparable to the incidence rates observed in Norway, Sweden and the United States, lower than those in United Kingdom, but higher than in Spain and Vilnius. The incidence rates of MPA are significantly higher in Japan, whereas GPA and CSS have rarely been diagnosed. Background: Giant Cell Arteritis (GCA) represents a medical emergency due to risk of permanent vision loss and/or cerebrovascular insults. Polymyalgia rheumatic (PMR) frequently coexists with GCA 1 . No diagnostic or prognostic markers are yet known for GCA and predicting relapses during steroid therapy tapering is difficult. Biomarkers, such as serum amyloid A (SAA) and interleukin-6 (IL-6) provide added value for monitoring inflammation and a recent investigational study indicated the potential use of neutrophils and their surface markers in GCA pathogenesis 2 . Objectives: To determine the percentage of neutrophils, T and B cells, and the mean fluorescence intensity (MFI) of L-selectin (CD62L) and integrin αM (CD11b) on CD16 + neutrophils in peripheral blood of newly diagnosed, untreated GCA and PMR patients vs. healthy controls (time 0) and at GCA follow-up (7, 30 and 90 days after therapy). Methods: Flow cytometry of stained, lysed and fixed whole blood 2 was performed in 10 GCA patients (6 followed longitudinally), 7 PMR patients and 5 healthy controls (7-colour immunophenotyping kit, Miltenyi). Levels of SAA and IL-6 were measured in sera of GCA patients (n=6) using nephelometry and ELISA, respectively. Results: Percentage of neutrophils was significantly higher at time 0 in GCA and PMR patients compared to healthy controls. Expression of both CD62L and CD11b on CD16 + neutrophils was also higher in GCA and PMR patients, as compared to healthy controls. Longitudinally, GCA patients showed an initial decrease in percentage of neutrophils at day 7 in comparison with time 0, increasing on days 30 and 90, while both T (CD4 + ) and B cells exhibited a significant elevation in % at day 7, with a decline at days 30 and 90. The MFI of neutrophil CD62L steadily decreased from day 0 (85.80±45.45) to day 7 (71.99±29.93) and day 30 (57.61±42.17), while showing a substantial increase on day 90 (88.54±60.35). CD11b expression diminished initially and remained reduced on day 90. Levels of SAA and IL-6 declined sharply from day 0 to 7 (>10-fold drop) and day 30, with gradual elevation of both on day 90. Conclusions: Neutrophil CD62L may represent a good surface marker for monitoring disease progression following glucocorticoid tapering. SAA and IL-6 exhibit a sharp decrease at early time points, increasing at day 90. In the future, a larger, longer study of neutrophils and their CD62L expression could support clinicians in their decision when and how to re-evaluate therapy in GCA patients. 
